FDA demonizes pharma over generics, but most company reputations can take the blow

The FDA is taking pharma to the woodshed again, this time over generic drug stalling tactics. Recently, the agency published an online list of pharma companies that together have racked up 150 complaints from generics makers seeking samples.

But while that probably feels like familiar public shaming territory for pharma, it’s not likely to end up causing broader damage to the reputations of the companies and brands named, one expert says.